The FDA granted Breakthrough Device designation to an mRNA Gene Biomarker blood-based assay manufactured by Laguna Diagnostics, announced April 28.
Breakthrough Device FDA designation
Phase 3 Clinical trial phase
26 Weeks Treatment period
Schizophrenia Condition studied